Fibromyalgia News and Research

Latest Fibromyalgia News and Research

From fatigued to fantastic! You CAN effectively treat CFS, fatigue, fibromyalgia and muscle pain

The “perfect storm” for Fibromyalgia, CFS/ME, and fatigue in general is preparing to hit. A combination of poor nutrition, decreasing sleep, increasing stress and environmental toxins has created a human energy crisis of unprecedented proportions. Over the past 10 years, the incidence of Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FMS) has exploded by 400 to 1000 percent, as documented in five separate studies. The numbers for those with CFS in the U.S., previously estimated at 500,000, are now being re-tallied at closer to 1- 2.5 million. Previous estimates placed the number of Americans with FMS at 6 million. Studies worldwide suggest this has likely gone up in the last decade to ~ 12-24 million Americans! Meanwhile, ¼ of Americans suffer with chronic pain and most are fatigued.

28 Mar 2011

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that the ongoing clinical trial of its Trimesta drug candidate has received an additional $409,426 in grant funding from the National Multiple Sclerosis Society.

28 Mar 2011

HCG hormone therapy may benefit patients with intractable pain

Results from a small study of intractable pain patients being treated with the human chorionic gonadotropin (HCG) hormone reported that they had experienced pain free hours in the past month. These results were presented at a poster session at the American Academy of Pain Medicine's 27th Annual Meeting.

25 Mar 2011

Onset of chronic pain more often reported following a traffic accident

Individuals with poorer health or psychological issues may be prone to developing chronic widespread pain following a traumatic event. This new research, published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR), found that the onset of chronic pain was more often reported following a traffic accident than from other physically traumatic triggers.

21 Mar 2011

Pico-Tesla receives ISO certification for Resonator device

Pico-Tesla, The Magneceutical Company, has received the International Organization for Standardization 13485:2003 certificate for the "design, development, production, manufacture and distribution of resonator systems that generate a low-level electromagnetic field for the therapeutic treatment of disease."

15 Mar 2011

Meda's 2010 group sales decrease to SEK 11,571 million

“The Meda Group expects to achieve sales of about SEK 11,400 million and an EBITDA of about SEK 4,400 million.”

14 Feb 2011

Protect Pharma completes sale of two patents and patents-applications to Grunenthal

Protect Pharmaceutical Corporation announced that it has completed the sale of two patents and patents-applications to Grunenthal GmbH, a German specialty pharmaceutical company that is a pioneer in pain drug discovery and research. The patent portfolio includes innovative pain drugs that address the large and underserved pain market.

9 Feb 2011

Adeona to sell 2.85 million common stock at $1.40 per share

Adeona Pharmaceuticals, a developer of innovative medicines for serious central nervous system diseases, announced today that it has executed an agreement for the sale of approximately 2.85 million shares of its common stock at $1.40 per share to two new institutional investors in a registered direct offering for $4 million in gross proceeds.

29 Jan 2011

Hand-held PDA devices for recording daily symptoms help fibromyalgia patients: Study

Hand-held PDA devices for recording daily symptoms are helping fibromyalgia patients and their doctors better understand links between pain, emotional distress and fatigue in this complex pain disorder, according to research reported in The Journal of Pain, the peer review publications of the American Pain Society.

28 Jan 2011

Chiropractic treatment helps female Army Brigadier General to battle against fibromyalgia

After 27 years of service, decorated U.S. Army Brigadier General Becky Halstead (Retired), the first female West Point graduate in U.S. history to command at the strategic level in Iraq and Afghanistan, decided to retire after being diagnosed with fibromyalgia - a medically unexplained syndrome affecting the muscles and connective tissues.

25 Jan 2011

Chelsea reports top-line data from Phase III NORTHERA extension study in NOH

Chelsea Therapeutics International, Ltd. reported new 12-month data from Study 303, a safety extension study from its Phase III NORTHERA™ (droxidopa) registration program in symptomatic neurogenic orthostatic hypotension (NOH). Preliminary, top-line results demonstrate Northera provides clinically meaningful and durable symptomatic improvements in patients with NOH throughout a one-year observation period.

20 Jan 2011

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.11 in the third quarter of fiscal 2011 after taking a charge for a new product licensing fee of $66.1 million or $0.23 per share, net of tax.

18 Jan 2011

Pico-Tesla commences placebo-controlled Magneceutical Therapy study for Alzheimer's disease

Pico-Tesla, The Magneceutical Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have Alzheimer's disease symptoms.

6 Jan 2011

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

Pico-Tesla, The Magneceutical Company, announced that it has expanded its ongoing Phase III pivotal clinical trial by adding three Principal Investigators, including two university-affiliated clinicians: one in Denver; and one in Tampa.

5 Jan 2011

New study reports close association between obesity and fibromyalgia

Afflicting up to 5 percent of the U.S. population, mostly women, fibromyalgia is characterized by widespread pain and range of function problems. A new study in The Journal of Pain reports there is close association between obesity and disability in fibromyalgia patients.

29 Dec 2010

Ramius/RP Group extend tender offer to acquire Cypress Bioscience

Ramius V&O Acquisition LLC, affiliates of Ramius LLC (collectively, "Ramius") and affiliates of Royalty Pharma (together with Ramius and Purchaser, the "Ramius/RP Group") announced today that the Ramius/RP Group is extending its previously announced tender offer to acquire all of the outstanding shares of common stock of Cypress Bioscience, Inc., a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, until Midnight, January 5, 2011, unless the offer is otherwise extended.

22 Dec 2010

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.

20 Dec 2010

Adeona expands and enhances zinc-based product candidate portfolio

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that it has acquired access to clinical data supporting a zinc-based therapy for the prevention of infections in the elderly. This acquisition expands and enhances Adeona's zinc-based product candidate portfolio that already includes its proprietary zinc-based tablets for use in the dietary management of mild to moderate Alzheimer's disease and mild cognitive impairment patients, and age-related macular degeneration.

16 Dec 2010

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Pico-Tesla, The Magneceutical® Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have fibromyalgia. The pilot study seeks to determine whether the application of magnetic fields generated by Pico-Tesla's patented Resonator™ system can be effective as an adjunctive therapy to oral medications in ameliorating the symptoms of fibromyalgia.

16 Dec 2010

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

Fibromyalgia News and Research

Latest Fibromyalgia News and Research

From fatigued to fantastic! You CAN effectively treat CFS, fatigue, fibromyalgia and muscle pain

NMSS grants Adeona's ongoing Trimesta trial with $409,426 to treat MS

HCG hormone therapy may benefit patients with intractable pain

Onset of chronic pain more often reported following a traffic accident

Pico-Tesla receives ISO certification for Resonator device

Meda's 2010 group sales decrease to SEK 11,571 million

Protect Pharma completes sale of two patents and patents-applications to Grunenthal

Adeona to sell 2.85 million common stock at $1.40 per share

Hand-held PDA devices for recording daily symptoms help fibromyalgia patients: Study

Chiropractic treatment helps female Army Brigadier General to battle against fibromyalgia

Chelsea reports top-line data from Phase III NORTHERA extension study in NOH

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Pico-Tesla commences placebo-controlled Magneceutical Therapy study for Alzheimer's disease

Pico-Tesla announces expansion of Magneceutical Phase III trail for Parkinson's disease

New study reports close association between obesity and fibromyalgia

Ramius/RP Group extend tender offer to acquire Cypress Bioscience

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Adeona expands and enhances zinc-based product candidate portfolio

Pico-Tesla commences pilot study of Magneceutical Therapy in fibromyalgia patients

Depression drug appears effective in reducing pain associated with breast cancer treatment

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Fibromyalgia News and Research

Latest Fibromyalgia News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in